SpectRx faces Nasdaq downgrade/delisting
This article was originally published in Clinica
Executive Summary
Diabetes and POC diagnostics producer SpectRx is facing the threat of Nasdaq delisting as the ongoing depression in emerging life science share prices causes many smaller companies to fall below the listing requirements.